Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL49035 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL150929 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL7525209 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL11659 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL18260580 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL2902509 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL7921264 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL19974227 | 0.94 | SLC34A1 (0.50) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL22263534 | 0.94 | LMNA (0.40) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL22263543 | 0.94 | LMNA (0.40) | LMNASLC34A1KDM4ECYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912764-B2 | Anti-connexin antibody formulations | ALAMAB THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | claimed |
| CN-117512808-A | Preparation method of enamel-like composite fiber | 北京航空航天大学 | 2024-02-06 | — | — | CN | claimed |
| EP-4188544-A1 | ANTI-CONNEXIN ANTIBODY FORMULATIONS | Alamab Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| EP-4037703-A1 | ANTO-CONNEXIN ANTIBODY FORMULATIONS | Alamab Therapeutics, Inc. (US) | 2022-08-10 | — | — | EP | claimed |
| WO-2022026914-A1 | ANTI-CONNEXIN ANTIBODY FORMULATIONS | ALAMAB THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| US-20220033492-A1 | ANTI-CONNEXIN ANTIBODY FORMULATIONS | ALAMAB THERAPEUTICS, INC. | 2022-02-03 | — | — | US | claimed |
| WO-2021067775-A1 | ANTO-CONNEXIN ANTIBODY FORMULATIONS | ALAMAB THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| US-20210101974-A1 | ANTI-CONNEXIN ANTIBODY FORMULATIONS | ALAMAB THERAPEUTICS, INC. | 2021-04-08 | — | — | US | claimed |
| CN-102578144-B | Product and method for generating peracetic acid | BEIJING KANGFULE TECHNOLOGY CO LTD | 2014-04-02 | — | — | CN | claimed |
| CN-102578144-A | Product and method for generating peracetic acid | BEIJING KANGFULE TECHNOLOGY CO LTD | 2012-07-18 | — | — | CN | claimed |
| EP-2124899-A2 | STABLE PHARMACEUTICAL FORMULATIONS OF ATORVASTATIN MAGNESIUM SALT | Actavis Group hf. (IS) | 2009-12-02 | — | — | EP | claimed |
| WO-2008078341-A2 | STABLE PHARMACEUTICAL FORMULATIONS OF ATORVASTATIN MAGNESIUM SALT | ACTAVIS GROUP HF. (IS) | 2008-07-03 | — | — | WO | claimed |
| CN-1612752-A | Aqueous Sustained Release Protein Formulations | ORTHO MCNEIL PHARM INC (US) | 2005-05-04 | — | — | CN | claimed |
| US-11912764-B2 | Anti-connexin antibody formulations | ALAMAB THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117512808-A | Preparation method of enamel-like composite fiber | 北京航空航天大学 | 2024-02-06 | — | — | CN | disclosed |
| EP-4188544-A1 | ANTI-CONNEXIN ANTIBODY FORMULATIONS | Alamab Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-2124899-A2 | STABLE PHARMACEUTICAL FORMULATIONS OF ATORVASTATIN MAGNESIUM SALT | Actavis Group hf. (IS) | 2009-12-02 | — | — | EP | disclosed |
| EP-2117516-A2 | STABLE ATORVASTATIN FORMULATIONS | Actavis Group PTC EHF (IS) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008096377-A2 | STABLE ATORVASTATIN FORMULATIONS | ACTAVIS GROUP PTC EHF (IS) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008078341-A2 | STABLE PHARMACEUTICAL FORMULATIONS OF ATORVASTATIN MAGNESIUM SALT | ACTAVIS GROUP HF. (IS) | 2008-07-03 | — | — | WO | disclosed |